Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Mov Disord Clin Pract ; 11(5): 496-503, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38419568

RESUMO

BACKGROUND: Fatigue is a prevalent and debilitating symptom in neurological disorders, including spinocerebellar ataxias (SCAs). However, the risk factors of fatigue in the SCAs as well as its impact have not been well investigated. OBJECTIVES: To study the prevalence of fatigue in SCAs, the factors contributing to fatigue, and the influence of fatigue on quality of life. METHODS: Fatigue was assessed in 418 participants with SCA1, SCA2, SCA3, and SCA6 from the Clinical Research Consortium for the Study of Cerebellar Ataxia using the Fatigue Severity Scale. We conducted multi-variable linear regression models to examine the factors contributing to fatigue as well as the association between fatigue and quality of life. RESULTS: Fatigue was most prevalent in SCA3 (52.6%), followed by SCA1 (36.7%), SCA6 (35.7%), and SCA2 (35.6%). SCA cases with fatigue had more severe ataxia and worse depressive symptoms. In SCA3, those with fatigue had a longer disease duration and longer pathological CAG repeat numbers. In multi-variable models, depressive symptoms, but not ataxia severity, were associated with more severe fatigue. Fatigue, independent of ataxia and depression, contributed to worse quality of life in SCA3 and SCA6 at baseline, and fatigue continued affecting quality of life throughout the disease course in all types of SCA. CONCLUSIONS: Fatigue is a common symptom in SCAs and is closely related to depression. Fatigue significantly impacts patients' quality of life. Therefore, screening for fatigue should be considered a part of standard clinical care for SCAs.


Assuntos
Fadiga , Qualidade de Vida , Ataxias Espinocerebelares , Humanos , Qualidade de Vida/psicologia , Ataxias Espinocerebelares/psicologia , Ataxias Espinocerebelares/complicações , Ataxias Espinocerebelares/genética , Ataxias Espinocerebelares/epidemiologia , Masculino , Fadiga/psicologia , Fadiga/epidemiologia , Feminino , Pessoa de Meia-Idade , Adulto , Idoso , Índice de Gravidade de Doença , Prevalência , Depressão/epidemiologia , Depressão/psicologia
3.
Brain Commun ; 4(4): fcac165, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35822101

RESUMO

The prodromal phase of Parkinson's disease is characterized by aggregation of the misfolded pathogenic protein α-synuclein in select neural centres, co-occurring with non-motor symptoms including sensory and cognitive loss, and emotional disturbances. It is unclear whether neuronal loss is significant during the prodrome. Underlying these symptoms are synaptic impairments and aberrant neural network activity. However, the relationships between synaptic defects and network-level perturbations are not established. In experimental models, pathological α-synuclein not only impacts neurotransmission at the synaptic level, but also leads to changes in brain network-level oscillatory dynamics-both of which likely contribute to non-motor deficits observed in Parkinson's disease. Here we draw upon research from both human subjects and experimental models to propose a 'synapse to network prodrome cascade' wherein before overt cell death, pathological α-synuclein induces synaptic loss and contributes to aberrant network activity, which then gives rise to prodromal symptomology. As the disease progresses, abnormal patterns of neural activity ultimately lead to neuronal loss and clinical progression of disease. Finally, we outline goals and research needed to unravel the basis of functional impairments in Parkinson's disease and other α-synucleinopathies.

4.
Artigo em Inglês | MEDLINE | ID: mdl-35651920

RESUMO

Holmes Tremor (HT) is an irregular, slow-frequency (<4.5 Hz) tremor characterized by a combination of resting, postural, and action tremors mostly of the upper extremities. Symptoms of HT typically emerge 4 weeks to 2 years after a brain injury caused by a spectrum of etiologies. HT pathophysiology is thought to result from aberrant collateral axonal sprouting and synaptic dysfunction following neuronal damage. To date, the dopaminergic nigrostriatal system, cerebello-thalamo-cortical pathway, and dentate-rubro-olivary pathway have all been implicated in the clinical manifestations of HT. The diversity of HT etiologies usually requires a personalized treatment plan. Current treatment options include carbidopa-levodopa, levetiracetam, and trihexyphenidyl, and surgical management such as deep brain stimulation in selected medication-refractory patients. In this review we discuss the pathophysiology, etiology, neuroimaging, and the latest clinical guidelines for care and management of HT.


Assuntos
Encéfalo , Tremor , Cerebelo , Humanos , Neuroimagem , Tremor/diagnóstico , Tremor/tratamento farmacológico
6.
Neurol Clin ; 39(1): 209-229, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33223084

RESUMO

Botulinum neurotoxin (BoNT) is an effective treatment for many neurologic disorders. This article gives a comprehensive overview of the clinical applications of BoNT across the field of neurology.


Assuntos
Toxinas Botulínicas Tipo A/uso terapêutico , Doenças do Sistema Nervoso/tratamento farmacológico , Fármacos Neuromusculares/uso terapêutico , Humanos , Neurologia/métodos , Resultado do Tratamento
7.
Neurol Clin ; 39(1): 71-85, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33223090

RESUMO

"Deep brain stimulation is a safe and effective therapy for the management of a variety of neurologic conditions with Food and Drug Administration or humanitarian exception approval for Parkinson disease, dystonia, tremor, and obsessive-compulsive disorder. Advances in neurophysiology, neuroimaging, and technology have driven increasing interest in the potential benefits of neurostimulation in other neuropsychiatric conditions including dementia, depression, pain, Tourette syndrome, and epilepsy, among others. New anatomic or combined targets are being investigated in these conditions to improve symptoms refractory to medications or standard stimulation."


Assuntos
Doenças do Sistema Nervoso Central/terapia , Estimulação Encefálica Profunda/métodos , Estimulação Encefálica Profunda/tendências , Humanos
8.
Front Hum Neurosci ; 14: 584005, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33240066

RESUMO

Objectives: To study whether and to what extent the therapeutic impedance and current change under long-term deep brain stimulation (DBS) with constant stimulation settings, which could inform the role of constant current stimulation. Methods: Therapy impedance and current measurements were retrospectively collected from patients with Parkinson's disease (PD) undergoing DBS of the subthalamic nucleus (STN) or essential tremor (ET) undergoing ventral intermediate nucleus (VIM). Baseline and follow-up measurements were obtained for intervals of at least 6 months without changes in stimulation settings. The single longest interval of constant stimulation for each electrode was included. Temporal trends in impedance and current were analyzed as absolute and relative differences and as the rate of change. Results: Impedance and current data from 79 electrodes (60 in STN, 19 in VIM) in 44 patients (32 with PD, 12 with ET) met inclusion criteria. The duration between baseline and follow-up measurements with constant stimulation settings was 17 months (median, with an interquartile range of 12-26 months) in the mixed group. Therapy impedance decreased by 27 ± 12 Ω/year (mean ± 2 standard errors; p < 0.0001), and therapy current increased at a rate of 0.142 ± 0.063 mA/year (p < 0.0001). Similar results were observed in the STN and VIM subgroups. Conclusions: Impedance decreases gradually over time, even when stimulation settings are kept constant. The rate of decrease is smaller than previously reported, suggesting that changes in stimulation settings contribute to impedance drift. Stimulation-independent impedance drift is gradual but relevant to constant-current programming.

9.
Neurology ; 95(20): e2769-e2780, 2020 11 17.
Artigo em Inglês | MEDLINE | ID: mdl-33004605

RESUMO

OBJECTIVE: To empirically test whether apathy and impulse control disorders (ICDs) represent independent, opposite ends of a motivational spectrum. METHODS: In this single-center, cross-sectional study, we obtained retrospective demographics and clinical data for 887 patients with idiopathic Parkinson disease (PD) seen at a tertiary care center. Mood and motivation disturbances were classified using recommended cutoff scores from self-reported measures of apathy, ICD, anxiety, and depression. RESULTS: Prevalence rates included 29.0% of patients with PD with depression, 40.7% with anxiety, 41.3% with apathy, 27.6% with ICDs, and 17.0% with both apathy and ICD. The majority (61.6%) of people reporting clinically significant ICDs also reported clinically significant apathy, and more than a third of patients with apathy (41.3%) also reported elevated ICD. Anxiety and depression were highest in patients with both apathy and ≥1 ICDs. Dopamine agonist use was higher in people with only ICD compared to people with only apathy. Mood significantly interacted with demographic variables to predict motivational disturbances. CONCLUSIONS: Motivational disturbances are common comorbid conditions in patients with PD. In addition, these complex behavioral syndromes interact with mood in clinically important ways that may influence the design of future clinical trials and the development of novel therapies. This study challenges the concept of apathy and ICD in PD as opposite ends of a spectrum.


Assuntos
Ansiedade , Apatia/fisiologia , Depressão , Transtornos Disruptivos, de Controle do Impulso e da Conduta , Motivação/fisiologia , Doença de Parkinson , Idoso , Ansiedade/epidemiologia , Ansiedade/etiologia , Ansiedade/fisiopatologia , Estudos Transversais , Depressão/epidemiologia , Depressão/etiologia , Depressão/fisiopatologia , Transtornos Disruptivos, de Controle do Impulso e da Conduta/epidemiologia , Transtornos Disruptivos, de Controle do Impulso e da Conduta/etiologia , Transtornos Disruptivos, de Controle do Impulso e da Conduta/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/complicações , Doença de Parkinson/epidemiologia , Doença de Parkinson/fisiopatologia , Estudos Retrospectivos
10.
Curr Opin Behav Sci ; 31: 37-41, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33102640

RESUMO

Substance use is strongly associated with gambling, but the nature of this association can be difficult to determine. Rodents offer the opportunity to test causal models of these relationships through isolation of individual variables of interest. This review describes recent research in rodents showing: a) predisposing factors for both gambling-like behavior and substance use; b) exposure to drugs of abuse increasing gambling-like behavior; c) experience with gambling-like behavior increasing substance use; and d) links between gambling-like behavior and substance use in models of Parkinson's disease therapies. These findings reveal novel relationships between gambling and substance use, and highlight the utility of rodent models for future work in this area.

11.
Neurotherapeutics ; 17(4): 1582-1602, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32767032

RESUMO

Multiple system atrophy (MSA) is a progressive neurodegenerative disease variably associated with motor, nonmotor, and autonomic symptoms, resulting from putaminal and cerebellar degeneration and associated with glial cytoplasmic inclusions enriched with α-synuclein in oligodendrocytes and neurons. Although symptomatic treatment of MSA can provide significant improvements in quality of life, the benefit is often partial, limited by adverse effects, and fails to treat the underlying cause. Consistent with the multisystem nature of the disease and evidence that motor symptoms, autonomic failure, and depression drive patient assessments of quality of life, treatment is best achieved through a coordinated multidisciplinary approach driven by the patient's priorities and goals of care. Research into disease-modifying therapies is ongoing with a particular focus on synuclein-targeted therapies among others. This review focuses on both current management and emerging therapies for this devastating disease.


Assuntos
Gerenciamento Clínico , Atrofia de Múltiplos Sistemas/genética , Atrofia de Múltiplos Sistemas/terapia , Animais , Anti-Inflamatórios/administração & dosagem , Terapia Genética/métodos , Terapia Genética/tendências , Humanos , Atrofia de Múltiplos Sistemas/diagnóstico por imagem , Neurônios/patologia , Oligodendroglia/patologia , Qualidade de Vida , alfa-Sinucleína/genética
12.
Artigo em Inglês | MEDLINE | ID: mdl-32149014

RESUMO

Background: Botulinum neurotoxin therapy (BoNT) is a powerful tool for treating many neurologic disorders. The U.S. Food and Drug Administration (FDA)-approved maximum onabotulinum toxin A (OnaA) dose is 400 units (U) per visit, but higher doses are commonly necessary, particularly when treating multiple body regions. Methods: We collected demographics, OnaA dose, body regions injected and indications, patient-reported efficacy via 7-point Clinical Global Impression Scale (CGIS), and duration of benefit. Results: Sixty-eight patients were identified receiving OnaA >400 U/session. Dystonia (n = 44) and spasticity (n = 24) were the most common indications for high-dose OnaA. Mean duration of benefit was 9 weeks (standard deviation [SD] 3). More than 70% of patients self-reported "very much improved" or "much improved" at 6 month, 1 year, and last visit. No serious adverse effects were reported. Discussion: The majority of patients tolerated >400 U OnaA with continued benefit. OnaA doses >400 U may be safe and effective in appropriate patients.


Assuntos
Toxinas Botulínicas Tipo A/administração & dosagem , Distonia/tratamento farmacológico , Espasticidade Muscular/tratamento farmacológico , Fármacos Neuromusculares/administração & dosagem , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medidas de Resultados Relatados pelo Paciente , Estudos Retrospectivos , Fatores de Tempo , Resultado do Tratamento
13.
Artigo em Inglês | MEDLINE | ID: mdl-31565536

RESUMO

Clinical vignette: A 68-year-old man with Parkinson's disease (PD) had bilateral GPi DBS placed for management of his motor fluctuations. He developed stimulation-induced dyskinesia (SID) with left dorsal GPi stimulation. Clinical dilemma: What do we know about SID in PD patients with GPi DBS? What are the potential strategies used to maximize the DBS therapeutic benefit and minimize the side effects of stimulation? Clinical solution: Avoiding the contact implicated in SID and programming more ventral contacts, using lower voltage, frequency and pulse width and programming in bipolar configuration all appear to help minimize the SID and provide appropriate symptomatic motor control. Gap in knowledge: Little is known about SID in patients with PD who had GPi DBS therapy. More studies using volume of tissue activated and diffusion tensor imaging MRI are needed to localize specific tracts in or around the GPi that may be implicated in SID.


Assuntos
Estimulação Encefálica Profunda/efeitos adversos , Discinesias/etiologia , Globo Pálido , Doença de Parkinson/terapia , Idoso , Humanos , Masculino
14.
Wounds ; 27(2): 20-5, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25785904

RESUMO

Calcinosis cutis is a poorly understood process in which calcium salts deposit in the skin and subcutaneous tissues. Due to its multifactorial pathogenesis, several subtypes and potential etiologies have been described. Presented here is a case of bilateral pretibial calcinosis cutis in a patient on long-term tyrosine kinase inhibitor therapy for chronic myeloid leukemia. The patient initially presented with a right tibial ulceration treated with multiple surgical debridements, antibiotics, and negative pressure wound therapy. The wound was ultimately closed with a split-thickness skin graft. Relevant literature is examined and several possible mechanisms are discussed.


Assuntos
Calcinose/etiologia , Desbridamento/métodos , Úlcera da Perna/patologia , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Transplante de Pele/métodos , Pele/patologia , Cicatrização , Antibacterianos/administração & dosagem , Doxiciclina/administração & dosagem , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/complicações , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Masculino , Pessoa de Meia-Idade , Tratamento de Ferimentos com Pressão Negativa/métodos , Resultado do Tratamento
15.
J Neuropathol Exp Neurol ; 70(9): 811-26, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21865889

RESUMO

We studied the expression and distribution of the microtubule-severing enzyme spastin in 3 human glioblastoma cell lines (U87MG, U138MG, and T98G) and in clinical tissue samples representative of all grades of diffuse astrocytic gliomas (n = 45). In adult human brains, spastin was distributed predominantly in neuronsand neuropil puncta and, to a lesser extent, in glia. Compared with normal mature brain tissues, spastin expression and cellular distribution were increased in neoplastic glial phenotypes, especiallyin glioblastoma (p < 0.05 vs low-grade diffuse astrocytomas). Overlapping punctate and diffuse patterns of localization wereidentified in tumor cells in tissues and in interphase and mitotic cells ofglioblastoma cell lines. There was enrichment of spastin in the leading edges of cells in T98G glioblastoma cell cultures and in neoplastic cell populations in tumor specimens. Real-time polymerase chain reaction and immunoblotting experiments revealed greater levels of spastin messenger RNA and protein expression in theglioblastoma cell lines versus normal human astrocytes. Functional experiments indicated that spastin depletion resulted in reduced cell motility and higher cell proliferation of T98G cells. Toour knowledge, this is the first report of spastin involvement incellmotility. Collectively, our results indicate that spastinexpression in glioblastomas might be linked to tumor cell motility, migration, and invasion.


Assuntos
Adenosina Trifosfatases/metabolismo , Neoplasias Encefálicas/enzimologia , Movimento Celular/fisiologia , Proliferação de Células , Regulação Neoplásica da Expressão Gênica/fisiologia , Glioblastoma/enzimologia , Adenosina Trifosfatases/genética , Fatores Etários , Encéfalo/enzimologia , Encéfalo/patologia , Neoplasias Encefálicas/patologia , Contagem de Células/métodos , Linhagem Celular Tumoral , Criança , Feminino , Glioblastoma/patologia , Humanos , Lactente , Masculino , Microtúbulos , Pessoa de Meia-Idade , RNA Mensageiro/metabolismo , Espastina , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...